Genpact valuation snapshot — May 19, 2026
Price $31.35 | Market cap ~$5.31B

Genpact Limited (NYSE: G) passes all three hard screening criteria — three consecutive years of ROE above 15% (FY2023–FY2025), consistently growing free cash flow ($435M → $735M), and a trailing P/E of 8.93× representing a 47% discount to its own five-year average of 18×. The stock is down 31% year-to-date after Q1 2026 earnings that beat consensus but delivered cautious Q2 guidance. Key risks include a 62% spike in short interest to 7.78% of float, unquantified regulatory litigation in India, and minimal insider ownership. Q2 2026 earnings (est. August 4–6) are the primary near-term verification point.

| Period | Revenue | YoY growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| FY2023 | $4.48B | +2.4% | 35.1% | 14.1% | 14.1%* |
| FY2024 | $4.77B | +6.5% | 35.5% | 14.7% | 10.8% |
| FY2025 | $5.08B | +6.6% | 36.0% | 14.8% | 10.9% |
| Q1 2026 | $1.30B | +6.7% | 36.4% | 15.3% | 11.4% |
| Company | Market cap | Trailing P/E | Forward P/E | EV/EBITDA | P/B | ROE |
|---|---|---|---|---|---|---|
| Genpact (G) | $5.31B | 8.93 | 11.58 | 7.10 | 2.15 | 21.9% |
| Cognizant (CTSH) | $33.4B | 10.23 | 12.96 | 8.97 | 2.21 | 16.7% |
| EXL Service (EXLS) | $4.43B | 17.53 | 12.72 | 12.60 | 5.70 | 28.1% |
| WNS Holdings (WNS) | $3.24B | 20.87 | 15.92 | 15.33 | 4.07 | 21.2% |
| Infosys (INFY) | $68.6B | 14.93 | 20.78 | 14.62 | 6.17 | — |
| Accenture (ACN) | $109.0B | 13.83 | 12.40 | 8.48 | 3.50 | — |
Add more perspectives or context around this Drop.